XTL Biopharmaceuticals Ltd (XTLB) — Cash Flow-to-Debt Ratio
XTL Biopharmaceuticals Ltd (XTLB) has a Cash Flow-to-Debt Ratio of -0.10x as of December 2017, meaning its operating cash flow of ILA-301.00K could theoretically repay 0% of its total liabilities (ILA2.97 Million) in one year. Explore XTL Biopharmaceuticals Ltd (XTLB) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
XTL Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for XTL Biopharmaceuticals Ltd across 12 annual periods. Also explore XTL Biopharmaceuticals Ltd (XTLB) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for XTL Biopharmaceuticals Ltd (2013–2024)
Year-by-year debt coverage analysis for XTL Biopharmaceuticals Ltd. For market capitalisation and broader financial context, see XTLB market cap.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.52x | ILA-1.62 Million | ILA3.12 Million | ▲ +84.9% |
| 2023 | -3.43x | ILA-707.00K | ILA206.00K | ▲ +28.8% |
| 2022 | -4.82x | ILA-901.00K | ILA187.00K | ▼ -490.2% |
| 2021 | -0.82x | ILA-1.05 Million | ILA1.28 Million | ▲ +75.6% |
| 2020 | -3.35x | ILA-850.00K | ILA254.00K | ▲ +14.5% |
| 2019 | -3.91x | ILA-908.00K | ILA232.00K | ▼ -21.3% |
| 2018 | -3.23x | ILA-816.00K | ILA253.00K | ▼ -750.6% |
| 2017 | -0.38x | ILA-1.12 Million | ILA2.97 Million | ▲ +92.8% |
| 2016 | -5.25x | ILA-1.73 Million | ILA330.00K | ▼ -23.0% |
| 2015 | -4.27x | ILA-1.86 Million | ILA436.00K | ▼ -66.8% |
| 2014 | -2.56x | ILA-2.47 Million | ILA965.00K | ▼ -26.0% |
| 2013 | -2.03x | ILA-2.50 Million | ILA1.23 Million | — |